Analia Carmo

Dr. Analia Carmo

Clinical Pathology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ACAnalia Carmo
Analia Carmo
MRMarilia Rocha
Marilia Rocha
PPPatricia Pereirinha
Patricia Pereirinha
RTRui Tomé
Rui Tomé
ECEulália Costa
Eulália Costa
The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins. However, all of these drugs presented one or more limitations associated with adverse reactions, administration route and more recently the development of resistance. To worsen this scenario, there has been an increase in fungal infections, especially in invasive systemic fungal infections that are particularly difficult to diagnose and treat. In 2022, the World Health Organization (WHO) published the first fungal priority pathogens list, alerting people to the increased incidence of invasive systemic fungal infections and to the associated risk of mortality/morbidity. The report also emphasized the need to rationally use existing drugs and develop new drugs. In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) characteristics and clinical applications. In parallel, we also addressed the contribution of fungi biology and genetics to the development of resistance to antifungal drugs. Considering that drug effectiveness also depends on the mammalian host, we provide an overview on the roles of therapeutic drug monitoring and pharmacogenomics as means to improve the outcome, prevent/reduce antifungal toxicity and prevent the emergence of antifungal resistance. Finally, we present the new antifungals and their main characteristics.

4 April 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Sara R. Martins-NevesSara R. Martins-Neves
Sara R. Martins-Neves
ÁLÁurio O Lopes
Áurio O Lopes
ACAnalia Carmo
Analia Carmo
APArtur Paiva
Artur Paiva
PSPaulo C Simões
Paulo C Simões
Célia GomesCélia Gomes
Célia Gomes
Background: Osteosarcoma is a bone-forming tumor of mesenchymal origin that presents a clinical pattern that is consistent with the cancer stem cell model. Cells with stem-like properties (CSCs) have been identified in several tumors and hypothesized as the responsible for the relative resistance to therapy and tumor relapses. In this study, we aimed to identify and characterize CSCs populations in a human osteosarcoma cell line and to explore their role in the responsiveness to conventional therapies. Methods: CSCs were isolated from the human MNNG/HOS cell line using the sphere formation assay and characterized in terms of self-renewal, mesenchymal stem cell properties, expression of pluripotency markers and ABC transporters, metabolic activity and tumorigenicity. Cell's sensitivity to conventional chemotherapeutic agents and to irradiation was analyzed and related with cell cycle-induced alterations and apoptosis. Results: The isolated CSCs were found to possess self-renewal and multipotential differentiation capabilities, express markers of pluripotent embryonic stem cells Oct4 and Nanog and the ABC transporters P-glycoprotein and BCRP, exhibit low metabolic activity and induce tumors in athymic mice. Compared with parental MNNG/HOS cells, CSCs were relatively more resistant to both chemotherapy and irradiation. None of the treatments have induced significant cell-cycle alterations and apoptosis in CSCs. Conclusions: MNNG/HOS osteosarcoma cells contain a stem-like cell population relatively resistant to conventional chemotherapeutic agents and irradiation. This resistant phenotype appears to be related with some stem features, namely the high expression of the drug efflux transporters P-glycoprotein and BCRP and their quiescent nature, which may provide a biological basis for resistance to therapy and recurrence commonly observed in osteosarcoma.

1 November 1998 in Experimental Eye Research
Verified
Journal Article
Closed access
ACAnalia Carmo
Analia Carmo
PRPedro Ramos
Pedro Ramos
ARAldina Reis
Aldina Reis
RPRui Proença
Rui Proença
JCJosé Cunha-Vaz
José Cunha-Vaz

19 June 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
ACAnalia Carmo
Analia Carmo
JPJoão Pereira‐Vaz
João Pereira‐Vaz
VMVanda Mota
Vanda Mota
AMAlexandra Mendes
Alexandra Mendes
CMCélia Morais
Célia Morais
FRFernando Rodrigues
Fernando Rodrigues


1 January 2010 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
ACAnalia Carmo
Analia Carmo
IPI. Patricio
I. Patricio
Maria Teresa CruzMaria Teresa Cruz
Maria Teresa Cruz
HCH. Carvalheiro
H. Carvalheiro
COC.R. Oliveira
C.R. Oliveira
MLM.C. Lopes
M.C. Lopes
Glioblastoma (GBM) is the most aggressive and malignant brain tumor. Recent studies indicated that glioma samples are characterized by increased expression of CXCR4, the CXCL12/SDF-1 chemokine rece...